I‐positron emission tomography (PET) score: Combining whole body iodine and 18F‐FDG PET/CT imaging to predict progression in structurally or biochemically incomplete thyroid cancer
Authors' conclusion
I-PET is a simple readily acquired imaging biomarker that potentially enhances the dynamic risk stratification and guide treatment in thyroid cancer.
Study context
- Population
- Patients aged >18 with DTC who had 18F-FDG PET and whole body scan (WBS) within a 6-month period, 2010–2020121 with follow-up
- Participants
- 142 patients
- Exposure
- I-PET score categories
- I-PET [0]n = 49reference
- I-PET [1]n = 10
- I-PET [2]n = 16
- I-PET [3]n = 46
- Outcome
- Progression: structural (RECIST 1.1 or further surgery) or biochemical (unstimulated Tg increasing >20% from baseline)
Methodological detailsthree independent nuclear medicine physician reviewers, Follow-up data obtained by chart review
- Three independent nuclear medicine physician reviewers
- Follow-up data obtained by chart review
Main finding
As reported in the abstract
Progression
P < 0.001
Observational data: associations, not effects.
Further findings
Progression in FDG +ve subgroups with SUVmax >5 (group B)
Commencing multikinase inhibitor therapy and mortality, I-PET [3B] vs other I-PET groups combined
- I-PET [3B] more likely to commence multikinase inhibitor therapy (p = 0.001)
- 9.6 times
- I-PET [3B] greater mortality (p = 0.003)
- 8 times
Original publication
I‐PET score: Combining whole body iodine and 18F‐FDG PET/CT imaging to predict progression in structurally or biochemically incomplete thyroid cancer. Clin Endocrinol (Oxf). Published 15 August 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →